MoonLake starts Phase 2 study of Nanobody sonelokimab in psoriatic arthritis

 

• MoonLake announces FDA clearance for Phase 2 clinical study of the Nanobody^® sonelokimab in active psoriatic arthritis
• Expected to enroll approximately 200 patients to assess the efficacy and safety of sonelokimab compared to placebo, with adalimumab as an active reference arm; recruitment expected to commence shortly in the United States and Europe
• This Phase 2 study represents an important step in psoriatic arthritis clinical development, assessing high threshold outcomes across joint and skin domains of this multi-faceted disease
• Sonelokimab is an investigational Nanobody^® designed to treat inflammatory diseases by inhibiting the IL-17A/A, IL-17A/F, and IL-17F/F dimers that drive inflammation, directly target sites of inflammation and penetrate difficult-to-reach inflamed tissues

https://www.biospace.com/article/releases/moonlake-immunotherapeutics-to-initiate-global-phase-2-study-of-the-nanobody-sonelokimab-in-patients-with-active-psoriatic-arthritis/